ClinicalTrials.gg
RecruitingNCT07200102Updated Oct 15, 2026

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

A Phase 1 interventional study of Selinexor in Multiple Myeloma, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 15, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies testing selinexor in Multiple Myeloma — 12 open to participants now, 21 under way, 3 of them phase 3. selinexor · Multiple Myeloma.

Planned enrollment
30th of 38
20 · median 45
Started
2026
with 1 other
Phase 1
7 of 38
3 open now
Primary completion
2029-04
later than 20 of 20 live
Registered
37th of 38
by date
Lead sponsor
2 of 38
Washington University School of Medicine

Among the 38 studies testing selinexor in Multiple Myeloma, this one is the 30th largest by planned enrollment, is one of 2 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 20 of the 20 other live ones, and was the 37th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 38 studies testing selinexor in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About selinexor

selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing selinexor in Multiple Myeloma, or all of them as a file.
02

Study summary

The outcomes in patients with relapsed or refractory multiple myeloma refractory to triple-therapy remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous T-cells to clear myeloma cells by targeting B-cell maturation antigen (BCMA). BCMA CAR-T therapy is not curative, and unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD rates and extend progression-free survival.

Selinexor is an exportin (XPO1) inhibitor with direct anti-tumor effect used often as an adjunct with other agents as bridging therapy prior to CAR-T. As selinexor does not affect T-cell yields or fitness, T-cell collection on selinexor for CAR-T manufacturing is safe.

The aim of this study is to evaluate the safety and toxicity of selinexor in relapsed or refractory multiple myeloma patients with high-risk features (adverse risk cytogenetics, less than complete response (CR) post CAR-T, or extramedullary disease) following BCMA CAR-T therapy. The investigators hypothesize that selinexor as maintenance therapy following CAR-T has the potential to act synergistically with CAR-T cells leading to more durable responses.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Cilta-cel
  • Selinexor
  • Multiple Myeloma
  • Maintenance
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with multiple myeloma who have received at least 1 , including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. Diagnosis must be confirmed. Patients with multiple myeloma with local amyloid deposition in the bone marrow are eligible. Only the following risk categories will be enrolled:

    • High risk myeloma, defined by the presence of at least one of the following features:

      • Deletion 17p and/or TP53 alteration:

        • Deletion of 17p with a cancer clonal fraction (CCF) ≥20%, assessed on CD138-positive/purified plasma cells, AND/OR
        • TP53 mutation identified using a validated next-generation sequencing (NGS)-based assay.
      • High-risk IgH translocation with chromosome 1 abnormality:

        • Presence of t(4;14), t(14;16), or t(14;20) in combination with either gain/amplification of 1q (1q+) and/or deletion of 1p32.
      • Chromosome 1p32 deletion patterns:

        • Monoallelic deletion of 1p32 occurring with gain/amplification of 1q, OR
        • Biallelic deletion of 1p32.
      • Elevated β2-microglobulin without renal dysfunction:

        • Serum β2-microglobulin ≥5.5 mg/L in the setting of normal renal function, defined as serum creatinine \<1.2 mg/dL.
      • Presence of extramedullary disease prior to receiving CAR-T OR
    • Standard risk myeloma with MRD-positive (MRD+) disease at MRD draw around Day 58-60 post CAR-T.
  • Received or planning to receive standard of care ciltacabtagene autoleucel (cilta-cel; Carvykti).
  • Able to monitor disease response by ClonoSEQ MRD testing.
  • At least 18 years of age.
  • performance status ≤ 2.
  • Adequate bone marrow and organ function as defined below:

    • ≥ 1.0 K/cumm
    • ≥ 50 K/cumm
    • ≥ 8.5 g/dL without blood transfusion within 7 days before C1D1.
    • Total ≤ 1.5 x IULN; patients with Gilbert's syndrome must have a total bilirubin \< 3 x IULN.
    • (SGOT)/ALT(SGPT) ≤ 2.5 x IULN
    • Calculated ≥ 15 mL/min by Cockcroft-Gault
  • The effects of selinexor on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate prior to C1D1 of selinexor, for the duration of study participation, and for 90 days after completion of selinexor. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s/he must inform her treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • MM with active CNS involvement.
  • Confirmed progressive disease by IMWG after CAR-T administration.
  • Unresolved cytokine release syndrome (CRS) or CAR-T neurologic toxicity.
  • Any unresolved non-hematologic grade ≥ 3 treatment-related toxicity from CAR-T.
  • Administration or planned administration of any other concomitant chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy which would be considered a treatment of multiple myeloma from Day 28 post-CAR-T cell therapy through discontinuation from study treatment. Note: patients may be on if they are being given for disorders other than multiple myeloma (e.g., adrenal insufficiency, rheumatoid arthritis)
  • Has received selinexor or another XPO1 inhibitor post-CART.
  • Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  • Prior organ transplant requiring therapy.
  • Prior or concurrent whose natural history has the potential to interfere with the safety or efficacy assessment of the regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial
  • Currently receiving any other investigational agents.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor or other agents used in the study.
  • Active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to C1D1 of selinexor (patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 of selinexor may enroll); active, unstable cardiovascular function, as indicated by the presence of symptomatic ischemia, uncontrolled conduction abnormalities (e.g. patients with ventricular or atrial tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), congestive heart failure of class ≥ 3 or known of \< 40%, or myocardial infraction within 3 months prior to C1D1 of selinexor therapy.
  • Major surgery within 28 days prior to C1D1 of selinexor
  • Pregnant and/or breastfeeding. Women of must have a negative pregnancy test within 7 days of C1D1 of selinexor.
  • -infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.
  • Evidence of chronic virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.
  • History of virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Selinexor

    Patients with high risk of relapse will receive maintenance selinexor starting at Day 30 (high risk MM patients) or after Day 58 (for MRD+ patients) post-cilta-cel infusion and will continue selinexor for up to 12 cycles. Selinexor will be given weekly on Days 1, 8, 15, and 22 of each 28-day cycle. The first 3 to 6 patients enrolled will be part of the safety run-in cohort; these patients will be monitored for dose-limiting toxicities during Cycle 1.

    Drug: Selinexor

Interventions

  • Selinexor will be provided by Karyopharm Therapeutics, Inc.

    Also known as: KPT-330, Xpovio

06

What researchers measure

Primary outcomes

  1. Rate of non-hematologic grade ≥ 3 treatment-related adverse events (excluding conditioning and CAR-T related adverse events) according to CTCAE v 6.0

    Time frame: From start of selinexor through 30 days after the last dose of selinexor (estimated to be 13 months)

  2. Tolerability as measured by rate of patients who received > 80% of cumulative selinexor dose during the study period

    Time frame: Through completion of selinexor treatment (estimated to be 12 months)

Secondary outcomes

  1. Rate of MRD negativity by clonoSEQ sensitive to 10-5

    Time frame: At 6 months after CAR-T infusion

  2. Rate of MRD negativity by clonoSEQ sensitive to 10-5

    Time frame: At 12 months after CAR-T infusion

  3. Rate of complete response (CR) and stringent CR (sCR) by IMWG response criteria

    * sCR: Stringent complete response requires all of the following: * CR as defined below * Normal free light chain ratio (0.26-1.65) * Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence * CR: Complete response requires all of the following: * Negative immunofixation on the serum and urine * Normal free light chain ratio (0.26-1.65) * \<5% plasma cells in the bone marrow aspirate * Disappearance of any soft tissue plasmacytomas

    Time frame: At 6 months after CAR-T infusion

  4. Rate of complete response (CR) and stringent CR (sCR) by IMWG response criteria

    * sCR: Stringent complete response requires all of the following: * CR as defined below * Normal free light chain ratio (0.26-1.65) * Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence * CR: Complete response requires all of the following: * Negative immunofixation on the serum and urine * Normal free light chain ratio (0.26-1.65) * \<5% plasma cells in the bone marrow aspirate * Disappearance of any soft tissue plasmacytomas

    Time frame: At 12 months after CAR-T infusion

  5. Progression-free survival (PFS)

    PFS is defined as: The time from initiation of treatment to the occurrence of either objective disease progression (by IMWG criteria) or death from any cause, whichever comes first.

    Time frame: At 6 months after CAR-T infusion

  6. Progression-free survival (PFS)

    PFS is defined as: The time from initiation of treatment to the occurrence of either objective disease progression (by IMWG criteria) or death from any cause, whichever comes first.

    Time frame: At 12 months after CAR-T infusion

  7. Time to progression (TTP)

    TTP is defined as: The interval from initiation of therapy to the first documentation of disease progression, as determined by IMWG criteria.

    Time frame: Through completion of follow-up (estimated to be 24 months)

  8. Duration of response (DOR)

    DOR is defined as: The time interval from the first documented evidence of a partial response or better after starting treatment by IMWG criteria to the occurrence of disease progression (by IMWG criteria) or death from any cause.

    Time frame: Through completion of follow-up (estimated to be 24 months)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Mark A Schroeder, M.D. · Contactmarkschroeder@wustl.edu · 314-454-8306
    • Mark A Schroeder, M.D. · Principal investigator
    • Arun Cumpelik, M.D., Ph.D. · Sub investigator
    • Feng Gao, Ph.D. · Sub investigator
    • Ravi Vij, M.D. · Sub investigator
    • Michael Slade, M.D. · Sub investigator
    • Keith Stockerl-Goldstein, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported after deidentification

Supporting information: Study protocol, Statistical analysis plan

Time frame: Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Analysis will be performed to achieve the aims of the approved proposal. Contact the PI regarding proposal submission and accessing data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2029, 37 months after the start.

Of 201 non-industry phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's planned 37 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Sep 30, 2025
StartActual
Mar 17, 2026
Primary completionEst.
Apr 30, 2029
CompletionEst.
Mar 31, 2031
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedDiagnosis of triple-class exposedDiagnosed with relapsed or refractory multiple myeloma (MM)who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. Diagnosis must be histologically confirmed. Patients with multiple myeloma with local amyloid deposition in the bone marrow are eligible. Only the following risk categories will be enrolled:
  • EditedReceived or planning to receive standard of care ciltacabtagene autoleucel (cilta-cel; Carvykti).
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosis of triple-class exposedDiagnosed with relapsed or refractory multiple myeloma (MM)who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. Diagnosis must be histologically confirmed. Patients with multiple myeloma with local amyloid deposition in the bone marrow are eligible. Only the following risk categories will be enrolled:
    • EditedReceived or planning to receive standard of care ciltacabtagene autoleucel (cilta-cel; Carvykti).
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07200102
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Mar 17, 2026
Primary completion
Apr 30, 2029 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Oct 15, 2026

Study contacts

Mark A Schroeder, M.D.
Contact
markschroeder@wustl.edu
314-454-8306
Mark A Schroeder, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion